Rohan Gandhi, Ph.D.
Executive Director, Translational Neuroscience
Dr. Gandhi is executive director of translational neuroscience at Autobahn Therapeutics
Dr. Gandhi has dedicated the past 15 years to bringing forward novel therapies for patients suffering from rare neurological diseases. He has worked across the research and development organization, focusing on the translation of preclinical discoveries to early clinical development success by utilizing a biomarker-driven approach. Prior to Autobahn, Dr. Gandhi was the global head of scientific affairs and extramural research at Kiniksa Pharmaceuticals where he oversaw all external collaborations and investigator-initiated studies. Recruited as the very first employee, he provided scientific due diligence and led negotiations that culminated in the in-licensing of 5 programs, led translational studies for 3 compounds that advanced from discovery to clinical development and worked beside the chief medical officer to serve as Kiniksa’s ambassador to external medical and scientific colleagues. Prior to joining Kiniksa, Dr. Gandhi led neuropharmacology efforts at Cubist Pharmaceuticals until its acquisition by Merck. Prior to that he was a neuroscientist at Vertex Pharmaceuticals where he contributed to CNS drug discovery programs in chronic pain, neurodegenerative, neuro-inflammatory, and rare genetic disorders. He earned a Ph.D. in neuroscience from the University of Kansas School of Medicine where his doctoral training focused on neuropharmacology and neuroanatomy. Dr. Gandhi received his B.A. (Honors) in biology and psychology from Coe College.